SOURCE: TapImmune Inc.

April 21, 2008 09:35 ET

TapImmune Provides Shareholder Update and Review

Company Announces Completion of Initial Sterility Testing

VANCOUVER, BC--(Marketwire - April 21, 2008) - TapImmune Inc. (OTCBB: TPIM) (FRANKFURT: GX1A) announces completion of initial testing on our bench made vaccine at AppTech. The company now has the necessary data to proceed with clinical grade vaccine stock production. Going forward, our work and development program includes phased manufacturing and production for both infectious disease adjuvant and cancer therapeutic vaccine candidates. These will culminate in toxicology studies and will coincide with pre-IND meeting preparation with the FDA and clinical protocols for our proposed phase 1 human studies.

This milestone is predicated on the back of a year where we have seen the completion of the UBC assignment agreement finally effecting our acquisition of the core technologies we developed under the world-wide license agreement. Our principal scientist Dr Jefferies and his team of researchers from the UBC have seen the publication of numerous of their papers in scientific and research journals around the world, discussing the validity of TAP as a therapeutic and adjuvant vaccine.

There is now also a vast amount of third party research data supporting and corroborating Dr Jefferies' initial description of the promising effect of TAP as a cancer therapy and their effect on tumor recognition.

This year it is our intention to bring all this research forward by initiating our first cGMP vaccine manufacturing contract. This will enable us to initiate toxicology testing and begin protocol design for a First-In-Man trial (phase 1).

We have also received positive news from the US Patent office giving us notice of allowance on one of our key follow on patents and a number of claims therein. We have filed additional patent applications to further strengthen and expand our IP position and are confidently now able to approach and work with industry leaders and potential partners in synergistic fields.

This sector in the biotech arena has seen some recent success stories in which larger pharmaceutical companies have taken partnership positions and invested in continued development of promising development stage therapeutics.

We are working diligently to make sure we are securing the right partners to enable us to achieve all we have set out to do. Additional, updates will be made available on our website, so please visit and sign up for additional news alerts.

About TapImmune

TapImmune is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, TAP vaccine, performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, or Transporters Associated with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected.

The Company's vaccine has shown, in preclinical tests, effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or 'accelerant' to enhance targeted vaccines against infectious diseases. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.

TapImmune is preparing GLP manufactured materials for the commencement of toxicology studies on the AdhTAP vaccine, leading to the initiation of a Phase I clinical trial. The Company is also developing a TAP-based vaccine adjuvant which existing preclinical data suggest increases the efficacy of targeted prophylactic vaccines by up to 1000 times.

Additional information on the Company can be found on its web site

Safe Harbor Statement

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-KSB and other SEC filings which are available through EDGAR at These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.

Contact Information

  • Contact for this Press Release:
    Denis Corin
    TapImmune Inc.
    604 264 8274